Success Metrics

Clinical Success Rate
100.0%

Based on 12 completed trials

Completion Rate
100%(12/12)
Active Trials
0(0%)
Results Posted
50%(6 trials)

Phase Distribution

Ph not_applicable
1
7%
Ph phase_1
1
7%
Ph phase_2
7
47%
Ph phase_4
4
27%

Phase Distribution

1

Early Stage

7

Mid Stage

4

Late Stage

Phase Distribution13 total trials
Phase 1Safety & dosage
1(7.7%)
Phase 2Efficacy & side effects
7(53.8%)
Phase 4Post-market surveillance
4(30.8%)
N/ANon-phased studies
1(7.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

12 of 12 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

15

all time

Status Distribution
Completed(12)
Other(3)

Detailed Status

Completed12
unknown3

Development Timeline

Analytics

Development Status

Total Trials
15
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (7.7%)
Phase 27 (53.8%)
Phase 44 (30.8%)
N/A1 (7.7%)

Trials by Status

completed1280%
unknown320%

Recent Activity

0 active trials
Showing 5 of 15
completedphase_2

The Efficacy of Intravitreal Aflibercept Injection in Improvement of Retinal Nonperfusion in Diabetic Retinopathy

NCT03006081
completedphase_2

IAI Versus Sham as Prophylaxis Against Conversion to Neovascular AMD

NCT02462889
completed

Change in Ocular Perfusion After Intravitreal Anti-VEGF in Patients with Age-related Maculopathy or Diabetic Macula Edema

NCT06878573
completedphase_2

Aflibercept Injection for Proliferative Diabetic Retinopathy

NCT01805297
completed

Outcomes of Tolerating Subretinal Fluid in Type 1 MNV and PCV

NCT05662943
View all 15 trials

Clinical Trials (15)

Showing 15 of 15 trials
NCT03006081Phase 2

The Efficacy of Intravitreal Aflibercept Injection in Improvement of Retinal Nonperfusion in Diabetic Retinopathy

Completed
NCT02462889Phase 2

IAI Versus Sham as Prophylaxis Against Conversion to Neovascular AMD

Completed
NCT06878573

Change in Ocular Perfusion After Intravitreal Anti-VEGF in Patients with Age-related Maculopathy or Diabetic Macula Edema

Completed
NCT01805297Phase 2

Aflibercept Injection for Proliferative Diabetic Retinopathy

Completed
NCT05662943

Outcomes of Tolerating Subretinal Fluid in Type 1 MNV and PCV

Completed
NCT04580147Phase 2

Intravitreal Aflibercept for the Prevention of Proliferative Vitreoretinopathy Following Retinal Detachment Repair

Unknown
NCT02689518Phase 4

EAGLE: Evaluating Genotypes Using Intravitreal Aflibercept Injection

Completed
NCT03405376Phase 4

Prospective Trial of Treat and Extend Aflibercept for Macular Edema Secondary to Branch Retinal Vein Occlusion

Unknown
NCT02392364Phase 4

Variable Interval Versus Set Interval Aflibercept for DME

Completed
NCT01773954Not Applicable

Repeated Eye Injections of Aflibercept for Treatment of Wet Age Related Macular Degeneration

Completed
NCT01657669Phase 4

Short-term Clinical Effects of Intravitreal Aflibercept Injection 2.0mg as a Predictor of Long-term Results

Unknown
NCT01710332Phase 2

The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy

Completed
NCT01971190Phase 2

Efficacy and Safety of Intravitreal Aflibercept Injection for Subacute Central Serous Chorioretinopathy

Completed
NCT01724554Phase 1

Impact of Intravitreal Aflibercept Injections on Capillary Non-Perfusion

Completed
NCT00789477Phase 2

DME And VEGF Trap-Eye [Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)] INvestigation of Clinical Impact

Completed

All 15 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
15